Eisai gets NerBloc marketing approval in Japan
NerBloc, a botulinum toxin type B neuromuscular-blocking agent has showed improvement in TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale) total score from baseline to week four compared with
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.